Isoyama S - Search Results

1

Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study.

Tanimoto T, Tada S, Fujita S, Hirakawa T, Matsumura M, Isoyama S, Ueno S, Hamai K, Tsuji N, Hirosawa H, Taniguchi T, Okamoto T, Omoto T, Kusunoki S, Maeda H, Ishikawa N. Tanimoto T, et al. Among authors: isoyama s. Respir Investig. 2022 May;60(3):418-424. doi: 10.1016/j.resinv.2022.02.004. Epub 2022 Mar 7. Respir Investig. 2022. PMID: 35307364 Free PMC article.

2

Efficacy of mepolizumab in elderly patients with severe asthma and overlapping COPD in real-world settings: A retrospective observational study.

Isoyama S, Ishikawa N, Hamai K, Matsumura M, Kobayashi H, Nomura A, Ueno S, Tanimoto T, Maeda H, Iwamoto H, Hattori N. Isoyama S, et al. Respir Investig. 2021 Jul;59(4):478-486. doi: 10.1016/j.resinv.2021.02.009. Epub 2021 Apr 11. Respir Investig. 2021. PMID: 33849780

3

Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study.

Isoyama S, Ishikawa N, Hamai K, Matsumura M, Kobayashi H, Nomura A, Ueno S, Tanimoto T, Maeda H, Iwamoto H, Hattori N. Isoyama S, et al. Intern Med. 2022;61(11):1663-1671. doi: 10.2169/internalmedicine.8180-21. Epub 2022 Jun 1. Intern Med. 2022. PMID: 35650114 Free PMC article.

4

First-line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD-L1: A case report.

Hamai K, Tanahashi H, Ueno S, Konishi H, Matsumura M, Nomura A, Nakamoto K, Isoyama S, Tanimoto T, Shoda H, Ishikawa N. Hamai K, et al. Among authors: isoyama s. Thorac Cancer. 2020 Jun;11(6):1716-1719. doi: 10.1111/1759-7714.13436. Epub 2020 Apr 14. Thorac Cancer. 2020. PMID: 32291904 Free PMC article.

5

Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1.

Masuda T, Fujitaka K, Suzuki T, Hamai K, Matsumoto N, Matsumura M, Isoyama S, Ueno S, Mito M, Yamaguchi K, Sakamoto S, Kawano R, Masuda K, Nishino R, Ishikawa N, Yamasaki M, Hattori N. Masuda T, et al. Among authors: isoyama s. Thorac Cancer. 2022 Jun;13(11):1611-1618. doi: 10.1111/1759-7714.14428. Epub 2022 Apr 30. Thorac Cancer. 2022. PMID: 35488720 Free PMC article. Clinical Trial.

6

Predictive role of circulatory levels of high-mobility group box 1 for radiation pneumonitis in patients with non-small cell lung cancer treated with definitive thoracic radiotherapy.

Isoyama S, Yamaguchi K, Imano N, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Nagata Y, Hattori N. Isoyama S, et al. Int J Clin Oncol. 2022 Nov;27(11):1698-1705. doi: 10.1007/s10147-022-02239-0. Epub 2022 Sep 3. Int J Clin Oncol. 2022. PMID: 36057047

7

[A Case of Small Cell Lung Cancer Diagnosed with Metastasis-Induced Acute Pancreatitis].

Ito N, Oshita H, Isoyama S, Senoo M, Kawasaki K, Okusaki K. Ito N, et al. Among authors: isoyama s. Gan To Kagaku Ryoho. 2019 Jul;46(7):1175-1177. Gan To Kagaku Ryoho. 2019. PMID: 31296825 Japanese.

8

Prediction of cell cycle distribution after drug exposure by high content imaging analysis using low-toxic DNA staining dye.

Takeuchi K, Nishimura Y, Matsubara T, Isoyama S, Suzuki A, Matsuura M, Dan S. Takeuchi K, et al. Among authors: isoyama s. Pharmacol Res Perspect. 2024 Jun;12(3):e1203. doi: 10.1002/prp2.1203. Pharmacol Res Perspect. 2024. PMID: 38682818 Free PMC article.

9

A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation.

Peng X, Huang X, Lulu TB, Jia W, Zhang S, Cohen L, Huang S, Fan J, Chen X, Liu S, Wang Y, Wang K, Isoyama S, Dan S, Wang F, Zhang Z, Elkabets M, Kong D. Peng X, et al. Among authors: isoyama s. Mol Cancer. 2024 Mar 14;23(1):54. doi: 10.1186/s12943-024-01978-0. Mol Cancer. 2024. PMID: 38486218 Free PMC article.

10

Subtype-selective induction of apoptosis in translocation-related sarcoma cells induced by PUMA and BIM upon treatment with pan-PI3K inhibitors.

Isoyama S, Tamaki N, Noguchi Y, Okamura M, Yoshimatsu Y, Kondo T, Suzuki T, Yaguchi SI, Dan S. Isoyama S, et al. Cell Death Dis. 2023 Feb 27;14(2):169. doi: 10.1038/s41419-023-05690-7. Cell Death Dis. 2023. PMID: 36849535 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

109 results

Search Page